A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro

Background. The detoxified TLR4-ligand Monophosphoryl Lipid A (MPLA) is the first approved TLR-agonist used as adjuvant in licensed vaccines but has not yet been explored as part of conjugated vaccines. Objective. To investigate the immune-modulating properties of a fusion protein consisting of MPLA...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunol Res
Päätekijät: Schülke, Stefan, Vogel, Lothar, Junker, Ann-Christine, Hanschmann, Kay-Martin, Flaczyk, Adam, Vieths, Stefan, Scheurer, Stephan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi Publishing Corporation 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4908266/
https://ncbi.nlm.nih.gov/pubmed/27340679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4156456
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia